Drug Trial Radar · NCT07037875
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
523
Actual
Start
Sep 11, 2025
Primary completion
Sep 28, 2026
Study completion Sep 28, 2026
Sponsor
- Lead sponsor
- Cinclus Pharma Holding ABIndustry
- Sponsor type
- Industry
- First posted
- Jun 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to find out how well linaprazan glurate can heal erosive esophagitis (EE) caused by gastroesophageal reflux disease (GERD), compared to lansoprazole, a commonly used medication. Researchers will also evaluate whether linaprazan glurate: * Reduces heartburn symptoms more effectively than lansoprazole * Is safe and well tolerated, based on physical exams, blood tests, and vital signs (heart rate, blood pressure, temperature, and breathing rate) * Causes any side effects during treatment * Has different effects depending on how much of the drug is in the blood * Works differently depending on participants' genes Participants must be between 18 to 80 years old and have EE due to GERD confirmed by an endoscopy. Participants cannot join if they have an active Helicobacter pylori (HP) infection or were treated for HP in the past 6 weeks or have taken antibiotics or bismuth-containing drugs in the past 6 weeks. The study is a randomized, double-blind, active comparator-controlled trial lasting up to 4 months. Randomized means that participants are assigned by chance (like flipping a coin) to one of the treatment groups and double-blind means neither the participants nor the study team will know which treatment is given. Participants will be placed into one of three groups (about 167 people in each group): * Linaprazan glurate 50 mg twice a day * Linaprazan glurate 50 mg once a day * Lansoprazole 30 mg once a day Everyone will take 2 tablets and 1 capsule by mouth daily for 8 weeks. Some tablets or capsules will be placebos (look like medicine but contain no active drug). Participants will: * Undergo an endoscopy in the beginning and after 4 weeks of treatment * If healing is not observed, another endoscopy may be done at 8 weeks * During the procedure, doctors will use a thin, flexible tube with a camera to look at the esophagus and take small tissue samples (biopsies) * Have blood and urine tests at clinic visits to check overall health * Receive electrocardiograms (ECGs) to monitor heart function * Complete daily questionnaires on an electronic device about symptoms and experiences
Conditions
- GERD (Gastroesophageal Reflux Disease)
Interventions
Linaprazan glurate 50 mg Twice Daily (BID)Drug
Participants in this group will receive a total daily dose of 100 mg of linaprazan glurate, administered as 50 mg in the morning and 50 mg in the evening. In the morning, they take one 50 mg linaprazan glurate tablet along with a placebo capsule that matches the appearance of the lansoprazole capsule. In the evening, they take another 50 mg linaprazan glurate tablet, without any additional placebo.
Linaprazan Glurate 50 mg Once Daily (QD)Drug
Participants in this group will receive a total daily dose of 50 mg of linaprazan glurate, taken once daily in the morning. In the morning, they take one 50 mg linaprazan glurate tablet along with a placebo capsule that mimics the lansoprazole capsule. In the evening, they take a placebo tablet that mimics the appearance of the linaprazan glurate tablet.
Lansoprazole 30 mg Once Daily (QD)Drug
Participants in this group will receive a total daily dose of 30 mg of lansoprazole, taken once daily in the morning. In the morning, they take one 30 mg lansoprazole capsule along with a placebo tablet that mimics the linaprazan glurate tablet. In the evening, they take another placebo tablet resembling linaprazan glurate.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Healing of EE at Week 4 as assessed by endoscopy in participants with Baseline EE LA grades C/D.Time frame: From enrollment to the end of treatment at 4 weeks.
Locations
87 sites in 8 countries. Site status is shown where the registry gives one.
Medical Center Hera
Kyustendil, Bulgaria
University Multiprofile Hospital for Active Treatment "Sveta Marina"
Pleven, Bulgaria
Medical Center "Futuremeds"
Plovdiv, Bulgaria
Multiprofile Hospital for Active Treatment "Sveti Panteleymon"
Plovdiv, Bulgaria
University Multiprofile Hospital for Active Treatment "Sveti Ivan Rilski", Sofia, Clinic of Gastroenterology
Sofia, Bulgaria
First Private Hospital Vratsa
Vratsa, Bulgaria
Multiprofile Hospital for Active Treatment "Sv. Ivan Rilski - 2003" OOD
Dupnitsa, Dupnitsa, Bulgaria
Multiprofile Hospital For Active Treatment St. Ivan Rilski Gorna Oriahovitsa EOOD
Gorna Oryahovitsa, Gorna Oryahovitsa, Bulgaria
Diagnosis - Consulting Centre 1
Sliven, Sliven, Bulgaria
Medical Center "Orange"
Sofia, Sofia City Province, Bulgaria
Multiprofile Hospital for Active Treatment - "Vita"
Sofia, Sofia City Province, Bulgaria
Diagnostic and Consulting Center Alexandrovska
Sofia, Sofia City Province, Bulgaria
Diagnostic Consultative Center - Focus-5
Sofia, Sofia City Province, Bulgaria
Medical Center Hera
Sofia, Sofia City Province, Bulgaria
University Multiprofile Hospital for Active Treatment "Tsaritsa Yoanna - ISUL"
Sofia, Sofia City Province, Bulgaria
University Multiprofile Hospital for Active Treatment and Emergency Medicine "N.I. Pirogov
Sofia, Sofia City Province, Bulgaria
20th Diagnostic Consultancy Center
Sofia, Sofia City Province, Bulgaria
SurGal Clinic s.r.o.
Brno, Czechia
University Hospital Brno
Brno, Czechia
PreventaMed s.r.o.
Olomouc, Czechia
Gastromedic s.r.o.
Pardubice, Czechia
Hospital Prachatice a.s.
Prachatice, Czechia
Endohope Morava s.r.o.
Zábřeh, Czechia
Military Hospital Brno, Internal Department
Brno, Brno, Czechia
Khozrevanidze's Clinic
Batumi, Georgia
LTD Health
Batumi, Georgia
JSC Georgian Clinics
Kutaisi, Georgia
LTD Aversi Clinic
Marneuli, Georgia
LTD Krol Medical Corporation
Tbilisi, Georgia
The New Hospitals
Tbilisi, Georgia
Israeli - Georgian Medical Research Clinic Healthycore LLC
Tbilisi, Georgia
Janmrtelobis Sakhli LLC
Tbilisi, Georgia
LLC Geo Hospitals
Tbilisi, Georgia
K. Eristavi National Center of Experimental and Clinical Surgery JSC
Tbilisi, Georgia
LTD Aversi Clinic
Tbilisi, Georgia
LEPL The First University Clinic of Tbilisi State Medical University
Tbilisi, Georgia
LTD The First Medical Center
Tbilisi, Georgia
Malkhaz Katsiashvili Multiprofile Emergency Medicine Center LLC
Tbilisi, Georgia
Diakonie Hospital
Mannheim, Baden-Wurttemberg, Germany
Medical Care Unit Dachau
Dachau, Bavaria, Germany
Showing 40 of 87 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.